What Is PT-141?

PT-141 is the research name for bremelanotide, a cyclic heptapeptide derived from Melanotan II, which itself was developed from alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike Melanotan II, PT-141 was specifically engineered to remove the tanning activity while preserving the central nervous system effects that researchers were interested in. Its molecular structure is a cyclic lactam analog, meaning the peptide chain forms a ring rather than a straight chain, which affects how it binds to its target receptors.

PT-141 acts on melanocortin receptors, specifically MC3R and MC4R, which are found in the brain rather than in peripheral tissues like blood vessels. This central mechanism distinguishes it from older sexual dysfunction drugs such as sildenafil, which work primarily by increasing blood flow in peripheral tissue. Because PT-141 targets the brain, researchers have described its mechanism as acting on the neural pathways involved in sexual motivation rather than on the physical plumbing of arousal.

The compound exists in two distinct regulatory contexts. Vyleesi, a branded subcutaneous injection of bremelanotide at 1.75 mg, received FDA approval in June 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. The research-chemical versions sold online under the name PT-141 are not FDA approved, are not manufactured under pharmaceutical-grade controls, and carry a different legal and safety profile than the approved drug.

How Does PT-141 Work at the Receptor Level?

Melanocortin receptors are a family of five G-protein-coupled receptors (MC1R through MC5R). PT-141 has the highest affinity for MC4R and MC3R. MC4R is expressed widely in the hypothalamus and limbic system, regions associated with motivation, reward, and sexual behavior. When PT-141 binds MC4R, it triggers downstream signaling cascades involving cyclic AMP that researchers believe modulate dopaminergic pathways tied to sexual desire.

Animal studies have helped map this mechanism in detail. Research in rats published in the early 2000s showed that direct administration of melanocortin agonists into the paraventricular nucleus of the hypothalamus produced erections and increased sexual behavior, pointing to a specific brain region as a key site of action. These findings informed the hypothesis that a systemically administered melanocortin agonist could produce similar effects in humans through the same pathway.

One important caveat is that receptor pharmacology in rodents does not always translate cleanly to humans. The distribution and density of MC4R in human brain regions differs from rodent models, and the behavioral outputs of receptor activation can differ across species. This is a standard limitation when interpreting preclinical mechanistic data.

What Does the Human Clinical Evidence Show?

The most rigorous human evidence comes from the trials that supported FDA approval of Vyleesi. Two pivotal Phase 3 randomized controlled trials, published in 2019 in Obstetrics and Gynecology, enrolled a combined total of over 1,200 premenopausal women with HSDD. Participants received either bremelanotide 1.75 mg or placebo via subcutaneous injection before anticipated sexual activity. The primary endpoints were changes in sexual desire scores and distress scores on validated questionnaires. Bremelanotide produced statistically significant improvements on both measures compared to placebo, though the absolute effect sizes were modest. Roughly 25 percent of participants on the drug met the threshold for a meaningful improvement in desire, compared to about 17 percent on placebo.

Earlier Phase 2 work in men with erectile dysfunction, published in the Journal of Sexual Medicine in 2004, enrolled 20 men in a crossover design. Participants received intranasal bremelanotide or placebo. The study reported improvements in erectile function scores, though the small sample size and the intranasal delivery route (which was later abandoned due to blood pressure concerns) limit how much weight this finding can carry.

A separate Phase 2 trial in women with female sexual arousal disorder, published in the Journal of Sexual Medicine in 2008, enrolled 18 women and used vaginal photoplethysmography alongside self-report measures. Bremelanotide increased genital arousal responses compared to placebo in that small sample. These early trials were useful for establishing proof of concept and guiding the larger Phase 3 program, but they are not sufficient on their own to draw firm conclusions.

The overall human evidence picture is this: there are two well-designed Phase 3 RCTs supporting a modest effect on sexual desire in premenopausal women with HSDD, and several smaller earlier trials in men and women with mixed designs and limited sample sizes. Outside of HSDD in premenopausal women, the human evidence base is thin.

What Are the Known Side Effects From Clinical Trials?

The Phase 3 trials documented a clear side effect profile. Nausea was the most common adverse event, reported by approximately 40 percent of participants receiving bremelanotide compared to about 1 percent on placebo. Flushing occurred in roughly 20 percent of the bremelanotide group. Headache and injection-site reactions were also more common in the active treatment arm. These effects were generally transient, resolving within a few hours, but nausea was severe enough that about 13 percent of participants discontinued the drug.

Blood pressure was a significant concern in earlier development. The intranasal formulation used in some Phase 2 trials produced clinically meaningful increases in blood pressure, which led the development team to switch to subcutaneous injection and to add a contraindication for people with cardiovascular disease in the approved Vyleesi label. The subcutaneous formulation still produces transient blood pressure increases, which is why the FDA label for Vyleesi includes a warning against use in people with uncontrolled hypertension or known cardiovascular disease.

Long-term safety data beyond the trial periods are limited. The approved Vyleesi label reflects the trial durations, which were not designed to assess effects over years of use. This is a standard gap in the evidence for many approved drugs, and it is a larger gap for the unapproved research-chemical versions where manufacturing quality and purity are not regulated.

Regulatory Status and the Research-Chemical Distinction

Vyleesi (bremelanotide injection, 1.75 mg) is FDA approved as of June 2019 for the treatment of HSDD in premenopausal women. It is a prescription drug, meaning it is dispensed only through a licensed prescriber and pharmacy. The approval is specific to that indication, that formulation, and that population. The FDA approval does not extend to other uses, other populations, or other delivery forms.

The compound sold online as PT-141 is a research chemical. It is not FDA approved, it is not manufactured under the Current Good Manufacturing Practice (cGMP) standards that apply to pharmaceutical drugs, and its purity and potency are not independently verified. Vendors sometimes market it for research purposes only, but in practice it is purchased and used by individuals outside of any clinical or research setting. This creates a meaningful gap between the controlled conditions of the clinical trials and real-world use.

From a legal standpoint, PT-141 occupies a gray area in the United States. It is not a scheduled controlled substance under the Controlled Substances Act, but it is also not approved for human use. The FDA has authority to take action against vendors selling unapproved drugs for human use. Anyone considering this compound should understand that the safety and efficacy data come from a pharmaceutical-grade product administered under medical supervision, not from the unregulated research-chemical supply chain.

Frequently asked questions

Is PT-141 the same thing as Vyleesi?

They share the same active molecule, bremelanotide, but they are not the same product. Vyleesi is an FDA-approved prescription drug manufactured to pharmaceutical standards, approved specifically for HSDD in premenopausal women. PT-141 is the name used for the research-chemical form, which is not FDA approved, not manufactured under pharmaceutical-grade controls, and not legally available for human use outside of a clinical trial or prescription setting.

Has PT-141 been studied in men?

Yes, early-phase trials did include men. A 2004 crossover study in the Journal of Sexual Medicine enrolled 20 men with erectile dysfunction and found improvements in erectile function scores with intranasal bremelanotide. However, the intranasal delivery route was later discontinued due to blood pressure concerns, and no large Phase 3 trials in men have been completed. The human evidence in men is limited to small, early-phase studies.

What does 'hypoactive sexual desire disorder' mean, and why is that the approved indication?

Hypoactive sexual desire disorder (HSDD) is a clinical diagnosis defined as persistently low or absent sexual desire that causes personal distress. It is not simply low libido in a general sense. The FDA approval for Vyleesi is specifically for premenopausal women with this diagnosis, because that is the population enrolled in the Phase 3 trials that demonstrated a statistically significant benefit. The approval does not cover postmenopausal women, men, or people without a formal HSDD diagnosis, because those groups were not studied in the pivotal trials.

Sources

  1. Clayton et al., 2019, Obstetrics and Gynecology (Phase 3 RCT) Pivotal Phase 3 trial supporting Vyleesi approval
  2. Kingsberg et al., 2019, Obstetrics and Gynecology (Phase 3 RCT) Second pivotal Phase 3 trial for bremelanotide
  3. Rosen et al., 2004, Journal of Sexual Medicine (Phase 2, men) Early Phase 2 trial in men with erectile dysfunction
  4. FDA Drug Approvals and Databases FDA drug approval and regulatory reference

Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds that are not approved for human use outside specific prescribed contexts. Always consult a qualified, licensed clinician before making any health decision.